SCHEMBL3313231

SCHEMBL3313231

COc1cc(CNS(=O)(=O)c2ccc(Cl)cc2)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPK1 P28482 1/20 0.41
MAPT P10636 1/20 0.39
CYP19A1 P11511 1/20 0.38
GAA P10253 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3314218 0.87 CYP3A4 (0.42) CYP3A4POLBSMN1; SMN2MAPK1MAPT
SCHEMBL2362967 0.85 CYP3A4 (0.50) CYP3A4POLBHPGDSMN1; SMN2MAPK1
SCHEMBL2352735 0.84 CYP3A4 (0.45) CYP3A4
SCHEMBL3312658 0.83 CYP3A4 (0.44) CYP3A4POLBMAPK1MAPT
SCHEMBL3313139 0.81 CYP3A4 (0.45) CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL2362843 0.78 CYP3A4 (0.48) CYP3A4ALDH1A1CYP1A2CYP2D6HPGD
SCHEMBL2348091 0.78 CYP3A4 (0.51) CYP3A4USP2ALDH1A1CYP1A2POLB
SCHEMBL3308176 0.77 CYP3A4 (0.42) CYP3A4POLBMAPTGAAMEN1
SCHEMBL3308904 0.77 CYP3A4 (0.42) CYP3A4ALDH1A1HPGDGAA
SCHEMBL2363467 0.77 CYP3A4 (0.43) CYP3A4ALDH1A1POLBHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP3A4 423/4885USP2 3016/4885ALDH1A1 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.